BioSpace News Archive

The global vaccine contract manufacturing market size was valued at USD 3.1 billion in 2022 and is projected to surpass around USD 8.92 billion by 2032, expanding at a remarkable CAGR of 11.2% from 2023 to 2032.

Regulatory News: Median Technologies is proud to have been chosen to join the ETIncelles scheme, an initiative created by the President of the French Republic, which aims to help 500 high growth potential SMEs in their transition to becoming an ETI, by 2027.

Vaxcyte, Inc. (Vaxcyte) (NASDAQ: PCVX) and Sutro Biopharma, Inc. (Sutro) (NASDAQ: STRO) today announced that Vaxcyte has exercised its option and entered into a manufacturing rights agreement with Sutro to obtain control over the development and manufacture of cell-free extract, a key component of Vaxcyte’s pneumococcal conjugate vaccine (PCV) franchise, which includes VAX-24 and VAX-31.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious oncologic and metabolic diseases, announced that Senthil Sundaram, the Company’s recently retired Chief Executive Officer, passed away on November 22, 2023, following his battle with cancer.

AnaptysBio, Inc. (Nasdaq: ANAB) today announced an exclusive license agreement for Centessa Pharmaceuticals’ (NASDAQ: CNTA) blood dendritic cell antigen 2 (BDCA2) modulator antibody portfolio, including lead asset CBS004 and related family of backup antibodies, for the treatment of autoimmune and inflammatory diseases.

Inari Medical, Inc. a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced the first patient enrollment in the PEERLESS II study.

Madrigal Pharmaceuticals, Inc. announced that the company granted equity awards to Carole Huntsman, the Company’s new Chief Commercial Officer and Senior Vice President and twelve other new employees, in each case with a grant date of November 20, 2023, as equity inducement awards under the terms of the company’s 2023 Inducement Plan.

ACELYRIN, INC. provided an update on its izokibep clinical development program, including its ongoing global Phase 2b/3 trial for izokibep in psoriatic arthritis.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 12,600 shares of the Company’s common stock at an exercise price per share of $14.06, which was the closing price on November 24, 2023, and restricted stock units to acquire a total of 6,300 shares of the Company’s common stock.

Today, the U.S. Food and Drug Administration approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment.